RLYB
Rallybio CorporationNASDAQHealthcare$8.12-3.68%ClosedMarket Cap: $43.0M
As of 2026-04-07
Valuation
P/E (TTM)
—
PEG
—
P/B
0.74
P/S
50.06
EV/EBITDA
-0.36
DCF Value
$11.37
FCF Yield
-69.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
99.7%
Operating Margin
-3853.6%
Net Margin
-1046.4%
ROE
-16.2%
ROA
-14.4%
ROIC
-56.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $222.0K | 98.6% | $-6.4M | $-5.9M | $-1.11 | — |
| FY 2025 | $858.0K | 89.3% | $-28.1M | $-9.0M | $-1.59 | — |
| Q3 2025 | $212.0K | 100.0% | $-6.9M | $16.0M | $2.84 | — |
| Q2 2025 | $212.0K | 100.0% | $-10.1M | $-9.7M | $-1.76 | — |
| Q1 2025 | $212.0K | 100.0% | $-9.7M | $-9.4M | $-1.68 | — |
| Q4 2024 | $38.0K | 21.1% | $-11.6M | $-11.0M | $-2.00 | — |
| FY 2024 | $636.0K | 100.0% | $-60.5M | $-57.8M | $-10.64 | — |
| Q3 2024 | $299.0K | 100.0% | $-12.1M | $-11.5M | $-2.08 | — |
| Q2 2024 | $299.0K | 88.6% | $-17.0M | $-16.2M | $-2.96 | — |
| Q1 2024 | $0.00 | -Infinity% | $-19.8M | $-19.0M | $-3.76 | — |
| Q4 2023 | $228.0K | 50.0% | $-21.1M | $-20.2M | $-4.00 | — |
| FY 2023 | $0.00 | -Infinity% | $-78.9M | $-74.6M | $-14.72 | — |